<DOC>
	<DOCNO>NCT01922336</DOCNO>
	<brief_summary>The purpose study compare pharmacokinetics , safety , tolerability immunogenicity SB2 Remicade ( EU source Remicade US source Remicade ) healthy subject .</brief_summary>
	<brief_title>Pharmacokinetic , Safety , Tolerability Immunogenicity Study SB2 Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Infliximab</mesh_term>
	<criteria>Healthy female subject nonchildbearing potential healthy male subject Have body weight 60.0 94.9 kg body mass index 20.0 29.9 kg/mÂ² , inclusive . history and/or current presence clinical significant atopic allergy , hypersensitivity allergic reaction , also include know suspected clinically relevant drug hypersensitivity component test reference IP formulation comparable drug . active latent Tuberculosis history Tuberculosis . history invasive systemic fungal infection opportunistic infection systemic local infection , know risk develop sepsis and/or know active inflammatory process serious infection associate hospitalisation and/or require intravenous antibiotic history and/or current cardiac disease receive live vaccine ( ) within 30 day prior Screening require live vaccine ( ) Screening final study visit . Intake medication halflife &gt; 24 h within 1 month 10 halflives medication prior administration investigational product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Pharmacokinetics</keyword>
</DOC>